These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...
The comments mark the latest in a number of trade-related threats unleashed by Trump in recent days. Trump said he plans to ...
In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...
Japanese pharmaceutical company Eisai Co and U.S. firm Biogen Inc said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease ...
Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...
Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...
The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback